Filovirus drug discovery using novel combinations of approved drugs

Award Information
Agency:
Department of Defense
Amount:
$99,999.00
Program:
SBIR
Contract:
DAMD17-05-C-0129
Solitcitation Year:
2005
Solicitation Number:
2005.1
Branch:
Office for Chemical and Biological Defense
Award Year:
2005
Phase:
Phase I
Agency Tracking Number:
C051-119-0150
Solicitation Topic Code:
CBD05-119
Small Business Information
APATH, LLC
893 N. Warson Road, St. Louis, MO, 63141
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Paul Olivo
 President & Chief Scientific Office
 (314) 812-8144
 olivo@apath.com
Business Contact
 L. Milton
Title: VP, Human Resources & Administratio
Phone: (314) 812-8160
Email: milton@apath.com
Research Institution
N/A
Abstract
The goal of this proposal is find novel combinations of approved drugs for the treatment and/or prevention of infection with filoviruses. Ebola and Marburg viruses, the only filoviruses, cause an acute hemorrhagic fever syndrome which has a high mortality rate and poses a significant bio-terrorism threat. There are currently no therapeutic agents available to treat filovirus infections and the development of such drugs is important for bio-defense. Apath has developed a novel, cell-based, infection-independent screening method that is based on replication of an Ebola virus minigenome. This proposal focuses on a strategy of combining existing drugs to discover combinations that have novel anti-filovirus activity. The Apath screening method is very amenable to identifying drug combinations that inhibit EBOV replication. The number of possible combinations of approved drugs, however, is enormous and so a recently described system will be used that identifies combinations of compounds that produce novel activity. This method streamlines the process of defining chemical relationships to enable the discovery of combinations of drugs that exhibit novel synergistic activity. The use of a library of approved drugs, all of which possess biologically activity and bioavailability, should facilitate the development of a therapeutic drug combination because they have desirable pharmaceutical properties.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government